Ye analysis Jubilant Ingrevia Ltd. ke liye hai.
Date of Analysis: February 4, 2026
Current Market Price (CMP): ₹652.00 (Approx)
Latest Result: Q3 FY26 (Dec 2025) – Declared Today (Feb 4, 2026)
📑 Equity Research Report: Jubilant Ingrevia Ltd.
1️⃣ Business Model & Work
Jubilant Ingrevia ek integrated Life Science products aur Specialty Chemicals company hai. Ye pehle Jubilant Life Sciences ka part thi, jo baad me demerger ke through alag entity bani.
- Core Business Segments:
- Specialty Chemicals (high margin): Pyridine, Picolines, Cyanopyridines. Isme company global leader hai (Top 2 globally). Ye pharma, agrochemical aur industrial clients ko supply karte hain.
- Nutrition & Health Solutions: Vitamin B3 (Niacinamide) – Global Top 2 producer. Animal Nutrition aur Human Nutrition products banati hai.
- Chemical Intermediates: Acetyls (Acetic Anhydride, Ethyl Acetate) – Ye volume-based business hai jo paints, packaging aur solvents me use hota hai.
- New Strategic Focus: CDMO (Contract Development & Manufacturing Organization) par aggressively focus kar rahi hai, jahan ye badi pharma/agro companies ke liye custom manufacturing karti hai.
- Market Position: Globally #1 in 11 Pyridine derivatives aur globally #2 in Vitamin B3.
- Revenue Mix (Approx): Specialty Chemicals (~45%), Nutrition (~18%), Chemical Intermediates (~37%).
2️⃣ Industry & Sector Analysis
- Sector Status: Challenging but Recovering. India ka specialty chemical sector pichle 1.5 saal se destocking (clients ka inventory kam karna) aur Chinese dumping se pareshan tha. 2025 ke end tak recovery ke signals dikh rahe hain.
- China + 1 Strategy: Global companies China par dependency kam kar rahi hain, jiska seedha fayda Jubilant jaise integrated players ko mil raha hai.
- Growth Drivers:
- Semiconductor Chemicals: Company ne electronic grade chemicals me entry announce ki hai (Future growth driver).
- Govt Policy: PLI schemes aur anti-dumping duties (jaise EU ne Chinese Choline Chloride par lagayi) Indian players ko favor kar rahi hain.
3️⃣ Latest Financial Performance (Consolidated)
⚠️ FRESH UPDATE (Feb 4, 2026): Company ne aaj hi apne Q3 FY26 (Dec 2025) ke results announce kiye hain. Results weak hain aur profit me badi girawat aayi hai.
Financial Trend Table (Figures in ₹ Crores):
| Period | Revenue | EBITDA | Net Profit (PAT) | EBITDA Margin % |
| Q3 FY26 (Dec 2025) | 1,050 | 128 | 46.9 | ~12.2% |
| Q2 FY26 (Sep 2025) | 1,121 | 146 | 70.0 | ~13.0% |
| Q3 FY25 (Dec 2024) | 1,057 | 138 | 69.4 | ~13.0% |
| FY 2025 (Full Year) | 4,178 | 519 | 251 | 12.4% |
| FY 2024 (Full Year) | 4,136 | 427 | 183 | 10.3% |
| FY 2023 (Full Year) | 4,773 | 549 | 308 | 11.5% |
- Result Analysis: Q3 FY26 me Revenue flat raha (-0.7% YoY) lekin Net Profit me ~32% ki bhari girawat (YoY) aayi hai. Iska main karan operational costs ka badhna aur margins par pressure hai.
- Margin Trend: Operating margins abhi bhi dabaav me hain (low teens me), jo ki specialty chemical companies ke liye historically kam maana jata hai.
- ROCE/ROE: Current ROE ~9-10% range me hai, jo ki mediocre hai (Ideally 15%+ hona chahiye).
4️⃣ Management & Shareholding (Latest Available)
Shareholding pattern stable hai, lekin institutional interest badh raha hai.
- Promoter Holding:45.22% (Stable).
- Pledged Shares: ~7.08% (Promoters ne kuch hissa girvi rakha hai, jo ek minor negative point hai).
- FIIs (Foreign Investors): 6.15% (Last quarter me mamooli badhotri).
- DIIs / Mutual Funds: 21.46% (Strong increase). Mutual Funds (jaise Edelweiss, UTI Small Cap) ne pichle 2-3 quarters me stake badhaya hai, jo long-term confidence dikhata hai.
- Public: ~27%.
- Management Quality: Jubilant Bhartia Group (Dominos Pizza India wale promoters) ka track record execution me strong raha hai. Management debt kam karne aur high-margin business (CDMO) ki taraf shift hone par focus kar rahi hai.
5️⃣ Valuation (Market Data: Feb 4, 2026)
- Current Market Price: ~₹652
- Market Cap: ~₹10,388 Cr
- P/E Ratio (TTM): ~36x (Earnings girne ki wajah se P/E optical roop se mehenga lag raha hai).
- P/B Ratio: ~3.4x.
- EV/EBITDA: ~19x (Historical average se thoda upar trade kar raha hai).
- Peer Comparison:
- Laxmi Organics: P/E ~45x (Expensive)
- Clean Science: P/E ~50x (Expensive)
- Jubilant Ingrevia: P/E ~36x (Relatively Fair, lekin earnings recovery zaruri hai).
6️⃣ Future Growth Triggers (3–5 Years)
- Capex Plan: Company ne ₹2,000 Crore ka capex plan banaya hai jo FY25-FY27 ke beech execute ho raha hai. Isse Specialty Chemicals aur CDMO capacity badhegi.
- Diketene Derivatives: Nayi capacity add ho rahi hai jo Laxmi Organics ke saath compete karegi lekin import substitution (bahaar se mangwana kam hoga) ka fayda milega.
- Agro-Active CDMO: Company ne 2 bade contracts sign kiye hain agro-chemicals ke liye, jinka revenue FY26 end/FY27 se aana shuru hoga.
- Semiconductor Focus: Greater Noida me R&D facility banayi ja rahi hai semiconductor chemicals ke liye. Ye ek high-entry barrier segment hai.
7️⃣ Present Situation (Current Outlook)
- Short-Term (Bearish): Aaj ke weak Q3 results (Profit down 32%) ki wajah se stock me short-term selling pressure aa sakta hai. ₹600 ka psychological support test ho sakta hai.
- Medium-Term: Company “Transition Phase” me hai—Commodity business (Intermediates) se Specialty/CDMO ki taraf shift ho rahi hai. Ye shift 2026 ke end tak visible results dega.
8️⃣ Risk & Red Flags
- Chinese Dumping: Agar China ne Vitamin B3 ya Pyridine ke prices aggressively giraye, to Jubilant ke margins turant gir jayenge.
- Chemical Intermediates Volatility: Acetic Acid ke prices global crude oil aur demand par depend karte hain, jo company ke control me nahi hai.
- Pledged Shares: 7% promoter pledging ek monitor karne layak point hai.
- Raw Material Cost: Crude oil prices badhne se margins squeeze ho sakte hain.
9️⃣ Final Verdict
Summary:
- Jubilant Ingrevia ek strong business franchise hai (Global Leader in Pyridine/Vitamin B3) lekin abhi cyclical downturn aur capex phase se guzar rahi hai.
- Latest results (Q3 FY26) ne disappoint kiya hai, isliye turant bhaag kar khareedne ki jaldi na karein.
- Growth story (CDMO + Diketene) abhi play out honi baaki hai (FY27 onwards).
Investor Suitability:
- Conservative Investor: ❌ WAIT. (Earnings volatility aur high valuation abhi comfortable entry point nahi de rahe).
- Aggressive / Long-term Investor: ✅ ACCUMULATE ON DIPS. (Agar stock ₹580-600 ki range me milta hai, to agle 3-4 saal ke liye CDMO growth story ke liye accha bet ho sakta hai).
Target Range (Estimated for FY27):
Agar company FY27 me ₹400-500 Cr ka PAT wapis achieve karti hai, to stock ₹800 – ₹900 ki range me ja sakta hai.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.